

February 5, 2026

**National Stock Exchange of India Limited (Symbol: INDUSINDBK)
BSE Limited (Scrip Code: 532187)
Luxembourg Stock Exchange**

Madam / Dear Sir,

Sub.: **Newspaper clippings**

Ref.: **Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Please find enclosed herewith the newspaper clippings published today i.e. February 05, 2026, pursuant to the SEBI circular on 'Ease of Doing Investment – Special Window for Transfer and Dematerialisation of Physical Securities' dated January 30, 2026.

This intimation is also being uploaded on the Bank's website at www.indusind.bank.in.

This is for your information and record.

Yours faithfully,

For IndusInd Bank Limited

**Anand Kumar Das
Company Secretary**

Encl: As above



Solitaire Corporate Park Office: IndusInd Bank Limited, Building No.7, Ground floor, Solitaire Corporate Park, Andheri –Ghatkopar Link Road, Chakala Andheri (E), Mumbai – 400 093, India, Tel: (022) 66412442

Registered Office: 2401 Gen. Thimmayya Road, Pune 411001, India

Contact us: (020) 2634 3201 | **Email us:** reachus@indusind.com | **Visit us:** www.indusind.bank.in

CIN: L65191PN1994PLC076333

Oriental Rail Infrastructure Limited

(Formerly known as Oriental Veneer Products Limited)

CIN: L35100MH1991PLC060686

Regd. Office: Survey No. 49, Village Aghai, via Kalyan Railway Station, Thane- 421 601; Tel No.: 022-61389400; E-mail: compliance@orientalrail.co.in; Website: www.orientalrail.com

Extract of Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2025

(Rs. in Lakhs except EPS)

Sr. No.	Particulars	Quarter ended			Nine months ended			Year ended
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1.	Revenue from Operations	16,857.53	13,339.40	15,281.79	41,987.36	46,200.80	60,221.55	
2.	Net Profit/ (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	1,831.68	1,423.31	1,025.88	4,085.87	3,240.50	4,440.17	
3.	Net Profit/ (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,831.68	1,423.31	1,025.88	4,085.87	3,240.50	4,440.17	
4.	Net Profit/ (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,382.46	1,066.57	752.49	3,036.41	2,384.20	2,921.59	
5.	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1,382.46	1,066.57	752.49	3,036.41	2,384.20	2,921.59	
6.	Paid-up Equity share capital	670.59	670.59	645.59	670.59	645.59	645.59	
7.	Other equity	-	-	-	-	-	-	
8.	Earnings Per Share (Face Value Rs. 1/- each)	2.06	1.59	1.17	4.53	3.89	4.68	
	Diluted:	2.06	1.59	1.17	4.53	3.89	4.68	

The Financial Results on standalone basis are as under

Sr. No.	Particulars	Quarter ended			Nine months ended			Year ended
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1.	Revenue from Operations	5,414.38	4,261.17	2,510.43	13,124.52	11,194.60	15,315.94	
2.	Net Profit/ (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	718.99	518.37	188.75	1,581.00	960.82	1,440.85	
3.	Net Profit/ (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	536.46	387.90	136.84	1,146.98	705.96	1,028.89	

Notes:

1. The above financial results have been reviewed by the Audit Committee & approved by the Board of Directors in its meeting held on February 04, 2026. The Statutory Auditors have carried out a Limited Review of the above financial results.

2. The above is an extract of the detailed format of Unaudited Financial Results for the quarter and nine months ended December 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results for the quarter and nine months ended December 31, 2025 are available on the Stock Exchange website www.bseindia.com and the website of the Company www.orientalrail.com.

3. The Company mainly operates in one segment namely "Indian Railway Products" and hence segment details are not required to be published.

4. Previous period/ year figures have been recast/ re-grouped to confirm to the current period's/ year's presentation

For and on behalf of Board of Director

Oriental Rail Infrastructure Limited

Sd/-

Karim N. Mithiborwala

Managing Director

DIN: 00171326

Place: Mumbai

Date : February 04, 2026

CGP

ORIENT GREEN POWER COMPANY LIMITED

ORIENT GREEN POWER COMPANY LIMITED

Corporate Identification Number (CIN) - L40108TN2006PLC061665

Regd. Office: Bazar Futura SV, 4th Floor, No.10/1, Venkatanarayana Road, T Nagar, Chennai – 600017

Visit us at: <https://www.orientgreenpower.com/> | E-mail: complianceofficer@orientgreenpower.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

The Board of Directors of the Company, at its meeting held on Wednesday, February 04, 2026 approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025.

The Unaudited Standalone and Consolidated Financial Results along with the Limited Review Reports have been posted on the Company's website at <https://www.orientgreenpower.com/investor.asp> and can be accessed by scanning the QR code.

By order of the Board

For Orient Green Power Company Limited

Sd/-

T Shivaraman

Managing Director & CEO

Place: Chennai

Date : February 04, 2026

Note: The above information is in accordance with Regulation 33 read with Regulation 47 (1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

IndusInd Bank

IndusInd Bank Limited

CIN: L65191PN1994PLC076333

Registered Office: 2401, Gen. Thimmayya Road (Cantonment), Pune - 411 001.

Secretarial & Investor Services: 701, Solitaire Corporate Park, 167, Guru Hargovindji Marg, Andheri (East), Mumbai - 400 093.

Tel No.: +91 6641 2487 / 6641 2359 • Email ID: investor@indusind.com • Website: www.indusind.bank.in

SPECIAL WINDOW FOR RE-LODGE MENT OF TRANSFER REQUESTS OF PHYSICAL SHARES OF INDUSIND BANK LIMITED

Pursuant to earlier, SEBI Circular No.SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025 and SEBI Circular No. SEBI/HO/38/13/11(2) 2026-MIRSD-PoD/I/3750/2026 dated January 30, 2026, all Shareholders of the Bank are hereby informed that a Special Window is open for a period of one year, from February 05, 2026 to February 04, 2027, for re-lodgement of transfer requests of physical shares, which were lodged prior to the deadline of April 1, 2019 and which were rejected / returned / not attended to due to deficiency in the documents / process / or otherwise.

Investors who have missed earlier deadline of March 31, 2021 (the cut-off date for re-lodgement of transfer deeds) & January 06, 2026, are encouraged to take this opportunity by furnishing the necessary documents to the Bank's Registrar and Transfer Agent M/s MUGF Intime India Private Limited (formerly Link Intime India Private Limited), at C-101, 247 Park, LBS Marg, Vikhroli (West), Mumbai - 400 083, Tel: +91 810811 6767 / 1800 1020 878, e-mail: investorhelpdesk@in.mpms.mugf.com.

For IndusInd Bank Ltd.

Sd/-

Anand Kumar Das

Company Secretary

Membership No. FCS-6950

Place: Mumbai

Date: February 04, 2026

E-Auction Sale Notice

Under Insolvency and Bankruptcy Code, 2016

C. Mahendra Exports Limited - In Liquidation

Regd office: Tower 'C', Office No. CC-6011, Bharat Diamond Bourse, Bandra Kurla Complex, Bandra (East), Mumbai - 400051

E-Auction Sale of Assets of C. Mahendra Exports Limited (in Liquidation) will be conducted on "As is where is", "As is what is", "Whatever there is" and "No recourse" basis.

DATE & TIME OF E-AUCTION: TUESDAY, FEBRUARY 24, 2026 FROM 11:30 AM TO 12:30 PM

Block	Asset	Reserve Price (Rs.)	Earnest Money Deposit (EMD) (Rs.)	Bid Incremental Amount (Rs.)
1.	Office Premises at 612 and 612-A Prasad Chambers, Swadeshi Mills Compound, Opera House, Mumbai - 400004	3,95,55,000	39,55,500	4,00,000
2.	Land, Building, along with miscellaneous Plant and Machinery situated at Plot No. 26/9-A & A/26/10, Udhna Udyognagar Sahakari Sangh Limited, Udhna, Surat - 394210, Gujarat (Land Area 1296 Sq. Mtrs.; Building Area 24,183 sq.ft.)	7,70,23,000	77,02,300	8,00,000
3.	Barren Land, Partly Jirayat & Sada-Pad Land situated at Survey No.474 & 476 Village Tisanagi Taluka: Kavathe - Mahankar, Dist: Sangli - 416405, Maharashtra. (Survey No. 474 - 5,900 sq. mtrs. & Survey No. 476 - 2200 sq. mtrs)	16,41,000	164,100	1,00,000
4.	Leased Land at Revenue Survey no.286/p, Village Shindodi Moti, Taluka - Abdasa, District: Kutch-Bhuj, Gujarat - 370645 admeasuring 10,000 sq. mtrs	1,78,200	17,820	10,000
5.	Equity Shares of C. Mahendra International Limited (112,800 Equity Shares of 10 each fully paid up)	10,33,64,100	1,03,36,410	10,00,000

Terms and Conditions of the E-Auction are as under:

1. The E-Auction sale shall be done through Baanknet, via the website <https://bbi.baanknet.com> ("Auction Portal").

2. The intending bidders are required to submit their Earnest Money Deposit ("EMD") through the auction portal latest by 23 February 2026, 6:00 PM.

3. Prospective bidders shall submit the requisite documents, including a declaration of eligibility under Section 29A of the Insolvency and Bankruptcy Code through the auction portal only. EMD of the highest bidder shall be forfeited if found ineligible anytime during the process.

4. All the terms, conditions, information related to assets and auction is provided in the Process Memorandum and is available on the auction portal. The requisition for information / data room has to be sent through Email id: circmel@gmail.com.

5. Interest bidders shall register, upload their eligibility documents, bid and receive confirmation of their bid by electronic means through auction portal only.

6. The Liquidator reserves the right to accept or reject or cancel any bid or modify any terms and conditions of process memorandum / E-Auction at any time without assigning any reason. The Liquidator also reserves the right to cancel the E-Auction at any time without assigning any reason.

Date: February 5, 2026

Place: Mumbai

Sd/-

Krishna Chamadia

Liquidator - C. Mahendra Exports Limited

IBBI Registration Number: IBBI/PA-001/IP-P00694/2017-18/11220

medanta

Global Health Limited

CIN: L85110DL2004PLC128319

Regd. Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India

Corp. Office: Medanta - The Medicity, Sector - 38, Gurugram, Haryana 122001, India

Tel: +91 124 483 4060 | E-mail: compliance@medanta.org | Website: <https://www.medanta.org>

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(₹ in Millions except EPS)

Sl. No.	Particulars	Quarter ended	Nine months ended	Quarter ended
		31.12.2025	31.12.2025	31.12.2024
		(Unaudited)	(Unaudited)	(Unaudited)
1	Revenue from operations	11,210.47	32,511.06	9,434.36
2	Net profit for the period (before tax and exceptional items)	1,563.81	5,287.59	1,890.68
3	Net profit for the period before tax (after exceptional items)	1,197.83	5,277.38	1,890.68
4	Net profit for the period after tax (after exceptional items)	950.33	4,124.15	1,428.58
5	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	956.53	4,123.45	1,457.41
6	Paid up equity share capital	537.58	537.58	537.17
7	Reserves (excluding Revaluation Reserve)*			
8	Earnings Per Share (of Rs 2/- each) -			
	Basic:	3.54	15.35	5.32
	Diluted:	3.54	15.32	5.32

* Reserves (excluding Revaluation Reserve) as on 31 March 2025 was Rs 33,326.93 Million.

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(₹ in Millions)

Sl. No.	Particulars	Quarter ended	Nine months ended	Quarter ended
		31.12.2025	31.12.2025	31.12.2024
		(Unaudited)	(Unaudited)	(Unaudited)
1	Revenue from operations	9,401.65	27,487.49	8,123.67
2	Net profit for the period (before tax and exceptional items)	1,380.86	4,858.02	1,752.75
3	Net profit for the period before tax (after exceptional items)	1,028.86	4,861.79	1,752.75
4	Net profit for the period after tax (after exceptional items)	799.07	3,720.70	1,313.86
5	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	803.83	3,719.73	1,339.41

Notes:

1. These results have been reviewed and recommended by the Audit Committee and accordingly approved by the Board of Directors of the Company at their respective meetings held on 4 February 2026. The result have been subjected to the limited review by the statutory auditors of the Company.

2. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the consolidated and standalone Quarter/Annual Financial Results are available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and also available at the company's website <https://www.medanta.org>.

By order of the Board

for Global Health Limited

Sd/-

Dr. Naresh Trehan

Chairman and Managing Director

Place: Gurugram

Date: 4 February 2026

EUREKA FORBES

EUREKA FORBES LIMITED

CIN : L27310MH2008PLC188478

Registered Office: B1/B2, 7th Floor, 701, Marathon Innova, Ganpatrao Kadam Marg, Lower Parel, Mumbai, Maharashtra - 400013, India.

Phone No.: +91 22 4882 1700 | Fax No.: +91 22 4882 1701 | Website: www.eurekaforbes.com | E-mail: compliance@eurekaforbes.com

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

(Rs. in Lakhs)

Sr. No.	Particulars	STANDALONE						CONSOLIDATED					
		Quarter ended		Nine Months ended		Year ended	Quarter ended		Nine Months ended		Year ended		
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Total income from operations	65,056.48	77,931.80	60,223.49	2,04,476.40	1,83,331.62	2,45,016.44	65,081.54	77,805.59	60,217.99	2,04,418.15	1,83,443.23	2,45,147.89
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items*)	5,280.31	8,316.35	4,694.68	18,765.92	14,791.73	21,379.25	5,413.20	8,496.88	4,731.37	19,117.23	15,123.34	21,652.09
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items*)	1,236.13	8,316.35	4,694.68	14,721.74	15,091.73	21,886.94	1,369.02	8,496.88	4,731.37	15,073.05	15,423.34	22,069.78
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items*)	900.22	6,158.86	3,482.22	10,911.30	11,253.47	16,328.65	997.88	6,291.75	3,503.36	11,159.54	11,493.37	16,441.47
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,197.29	6,073.03	3,423.36	11,036.68	11,076.93	15,985.24	1,283.93	6,248.12	3,420.28	11,314.26	11,298.21	16,096.51
6	Equity Share Capital	19,349.18	19,349.18	19,347.92	19,349.18	19,347.92	19,347.92	19,349.18	19,349.18	19,347.92	19,349.18	19,347.92	19,347.92
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet)						4,19,149.15						4,21,520.82
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -												
	1. Basic:	0.46	3.17	1.80	5.61	5.82	8.40	0.52	3.23	1.81	5.74	5.94	8.46
	2. Diluted:*	0.46*	3.17*	1.79*	5.61*	5.80*	8.40*	0.52*	3.23*	1.81*	5.74*	5.92*	8.46*

* Impact due to grant of Stock Options has been considered while arriving at the diluted EPS.

* Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.

Notes:

1. The Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2025 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 04, 2026.

2. The above is an extract of the detailed format of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2025 filed with Stock Exchanges under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the above Financial Results are available on the websites of Stock Exchanges (www.bseindia.com and www.nseindia.com) and Company's website at www.eurekaforbes.com. The same can be accessed on the Company's website by scanning the QR Code provided below:

For Eureka Forbes Limited

Sd/-

Pratik Pota

Managing Director & CEO

DIN : 00751178

Place: Mumbai

Date: February 04, 2026

Aarti Drugs Limited

Registered Office: Plot No. N-198, MIDC, Tarapur, Village Pamtermbhi, Dist. Palghar - 401 506, Maharashtra

CIN: L37060MH1984PLC055433 Email ID: investorrelations@aartidrugs.com Website: www.aartidrugs.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2025

(₹ In Lacs except for share data)

PARTICULARS	Standalone					Consolidated						
	Quarter Ended		Period Ended		Year Ended	Quarter Ended		Period Ended		Year Ended		
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025	
	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	
Total income	53,002	57,910	52,591	163,047	156,256	218,723	60,294	65,288	56,850	184,664	172,476	240,339
Net profit for the period (before tax, exceptional and/or extraordinary items)	2,171	5,578	5,203	12,274	12,808	19,875	2,902	6,041	5,076	14,054	14,062	21,177
Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-
Net profit for the period after Tax (after exceptional and/or extraordinary items)	3,384	4,178	3,853	12,426	9,583	15,731	4,055	4,516	3,709	13,968	10,533	16,810
Other Comprehensive Income (after tax)	-	-	-	-	-	113	31	-	(46)	43	31	159
Total Comprehensive Income for the period	3,384	4,178	3,853	12,426	9,583	15,844	4,086	4,516	3,663	14,011	10,563	16,969
Weighted average number of equity shares used for computing earning per share (face value of Rs. 10 each)	9,127	9,127	9,127	9,127	9,127	9,127	9,127	9,127	9,127	9,127	9,127	9,127
Earning per share (in Rs.) (not annualised)												
(a) Basic	3.71	4.58	4.22	13.61	10.50	17.18	4.44	4.95	4.06	15.30	11.54	18.35
(b) Diluted	3.71	4.58	4.22	13.61	10.50	17.18	4.44	4.95	4.06	15.30	11.54	18.35

Notes:

1) The above results for the Quarter & Period ended 31st December, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 3rd February, 2026.

2) The Board of Directors have declared interim Dividend of Rs. 2.00/- (Rupee Two) per Equity Share of Rs. 10/- each (20%) amounting to Rs. 18,25,40,000 for the Period ended 31st December, 2025.

3) As on December 31, 2025 the Company, has 3 (three) subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, Pinnacle Chile SpA and 1 (one) step down subsidiary, namely Pharma Go SpA.

4) The company has completed the buyback of 6,65,000 equity shares of face value of Rs. 10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding filing fees payable to the SEBI, advisors' fees, stock exchanges fee for usage of their platform for Buyback, transaction costs viz. brokerage, applicable taxes inter alia including Buyback tax, securities transaction tax, GST, stamp duty, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses etc.) ("Buyback Size") on September 24, 2024. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,27,00,000 divided into 9,12,70,000 Equity Shares of Rs.10/- each.

5) On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws ('New Labour Codes'). The Ministry of Labour & Employment has also published draft Central Rules and FAQs on aforesaid labour codes. The detailed impact assessment is currently in progress, necessary adjustments, if any, will be identified and appropriately accounted for in Q4 FY 2025-26.

6) Company has only one business segment i.e. pharmaceuticals.

7) The Company's new manufacturing plant at Sayakha, Gujarat has commenced commercial production/operations w.e.f. September 4, 2025.

8) Figures for the previous Quarter have been regrouped or rearranged wherever necessary.

9) The aforesaid Audited Financial Results are uploaded on the Company's website www.aartidrugs.com and also available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors. The Same data can be accessed by scanning the QR code provided below:

For Aarti Drugs Limited

Sd/-

Prakash M. Patil

Chairman, Managing Director & CEO

DIN: 00005618

Place: Mumbai

Date: 3rd February, 2026

WESTLIFE FOODWORLD LIMITED

Regd. Office : 1001, Tower - 3, 10th Floor, One International Center, Senapati Bapat Marg, Prabhadevi, Mumbai 400 013.

CIN No. : L65990MH1982PLC028593 Tel : 022-4913 5000 Fax : 022-4913 50